SAN

76.25

+0.43%↑

UCB

260.1

+1.76%↑

SHL.DE

39.75

-0.6%↓

ARGX

635.8

+0.89%↑

PHIA

25.07

+0.97%↑

SAN

76.25

+0.43%↑

UCB

260.1

+1.76%↑

SHL.DE

39.75

-0.6%↓

ARGX

635.8

+0.89%↑

PHIA

25.07

+0.97%↑

SAN

76.25

+0.43%↑

UCB

260.1

+1.76%↑

SHL.DE

39.75

-0.6%↓

ARGX

635.8

+0.89%↑

PHIA

25.07

+0.97%↑

SAN

76.25

+0.43%↑

UCB

260.1

+1.76%↑

SHL.DE

39.75

-0.6%↓

ARGX

635.8

+0.89%↑

PHIA

25.07

+0.97%↑

SAN

76.25

+0.43%↑

UCB

260.1

+1.76%↑

SHL.DE

39.75

-0.6%↓

ARGX

635.8

+0.89%↑

PHIA

25.07

+0.97%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

82.75 2.99

Résumé

Variation du prix de l'action

24h

Actuel

Min

81.45

Max

83.55

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

34.025

61.417

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+12.08% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

130M

4.1B

Ouverture précédente

79.76

Clôture précédente

82.75

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 mars 2026, 20:38 UTC

Résultats

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mars 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mars 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mars 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mars 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mars 2026, 23:35 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mars 2026, 23:06 UTC

Résultats

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mars 2026, 22:51 UTC

Principaux Événements d'Actualité

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mars 2026, 21:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mars 2026, 21:21 UTC

Résultats

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mars 2026, 21:15 UTC

Résultats

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mars 2026, 21:15 UTC

Acquisitions, Fusions, Rachats

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mars 2026, 21:14 UTC

Résultats

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mars 2026, 21:13 UTC

Résultats

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mars 2026, 21:12 UTC

Résultats

Franco-Nevada 4Q Rev $597.3M >FNV

10 mars 2026, 21:12 UTC

Résultats

Franco-Nevada 4Q EPS $1.90

10 mars 2026, 20:57 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mars 2026, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

10 mars 2026, 20:44 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mars 2026, 20:34 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

10 mars 2026, 20:34 UTC

Market Talk
Résultats

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mars 2026, 20:23 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mars 2026, 20:16 UTC

Résultats

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mars 2026, 20:14 UTC

Résultats

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mars 2026, 20:14 UTC

Résultats

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mars 2026, 20:13 UTC

Résultats

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mars 2026, 20:12 UTC

Résultats

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

12.08% hausse

Prévisions sur 12 Mois

Moyen 90 EUR  12.08%

Haut 90 EUR

Bas 90 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat